Cytokinetics, Incorporated
CYTK today announced positive data from a recently completed Phase
IIa "Evidence of Effect" clinical trial of tirasemtiv in patients with
generalized myasthenia gravis (MG). Tirasemtiv selectively activates the fast
skeletal muscle troponin complex by increasing its sensitivity to calcium
thereby increasing skeletal muscle force in response to neuronal input and
delaying the onset and reducing the degree of muscle fatigue. Tirasemtiv, the
lead drug candidate from the company's skeletal muscle contractility program,
is being evaluated as a potential treatment for amyotrophic lateral sclerosis
(ALS) in BENEFIT-ALS, an international Phase IIb clinical trial that is now
enrolling patients.
Phase IIa Clinical Trial in Patients with Myasthenia Gravis: Design and
Results
This Phase IIa Evidence of Effect clinical trial, known as CY 4023, was a
double-blind, randomized, three-period crossover, placebo-controlled,
pharmacokinetic and pharmacodynamic study of tirasemtiv in patients with
generalized MG. Patients enrolled in CY 4023 received single, oral,
double-blind doses of placebo, 250 mg, and 500 mg of tirasemtiv in random
order and approximately one week apart. The main objectives of this trial were
to assess the effects of tirasemtiv on various measures of muscle strength,
muscle fatigue and pulmonary function. Since CY 4023 was a
hypothesis-generating trial, no single primary efficacy endpoint was
pre-specified.
In CY 4023, at six hours after dosing, improvements (i.e., decreases) in the
Quantitative MG score (QMG) were related to the tirasemtiv dose in a
statistical significant manner (-0.49 QMG points per 250 mg; p = 0.02). The
QMG is a validated index of disease severity that is often employed as a
primary endpoint in clinical trials of patients with MG. In addition,
decreases in certain components of the QMG and their relationships to dose
were statistically significant or borderline significant. Also at six hours
after dosing in CY 4023, increases in the percent predicted forced vital
capacity were statistically significantly related to the dose level of
tirasemtiv (2.2% per 250 mg; p = 0.04), as were the individual comparisons of
each dose level of tirasemtiv versus placebo. Pending further analyses, more
complete results from CY 4023 are expected to be submitted for public
presentation at an upcoming clinical conference.
Both the 250 mg and 500 mg single oral doses of tirasemtiv studied in this
Phase IIa clinical trial were well-tolerated by the 32 patients enrolled in CY
4023; there were no premature terminations and no serious adverse events were
reported. The most commonly reported adverse event was dizziness which
increased in frequency with dose and was reported as mild in all but one case
that was classified as moderate.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in